Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Omkar PharmachemBOM:532167 52 PEG Ratio is 0.02 as of Jul. 29, 2026. GuruFocus rates BOM:532167 with a GF Score™ of 52/100 and a GF Value™ of ₹23.90 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 440 Business Services companies, Omkar Pharmachem ranks better than 99.77% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Omkar Pharmachem's PEG Ratio or its related term are showing as below:
BOM:532167'
s PEG Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.02
Current: 0.02
During the past 13 years, Omkar Pharmachem's highest PEG Ratio was 0.02. The lowest was 0.00. And the median was 0.00.
BOM:532167's PEG Ratio is ranked better than 99.77% of 440
companies
in the Business Services industry
Industry Median: 1.175
vs BOM:532167: 0.02
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Omkar Pharmachem (BOM:532167) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Omkar Pharmachem PEG Ratio Related Terms
Omkar Pharmachem PEG Ratio Historical Data
* Premium members only.
The historical data trend for Omkar Pharmachem's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:532167 vs CTAS, CPRT, GPN: PEG Ratio Comparison
For the Specialty Business Services subindustry, Omkar Pharmachem's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omkar Pharmachem PEG Ratio vs Business Services Industry
For the Business Services industry and Industrials sector, Omkar Pharmachem's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Omkar Pharmachem's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Omkar Pharmachem (BOM:532167) has a PEG Ratio of 0.02 as of Jul. 29, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Omkar Pharmachem and its competitors. According to the industry distribution chart, Omkar Pharmachem ranks #1 out of 440 companies in the Business Services industry, placing it in the top 0.2%.
Is Omkar Pharmachem's PEG Ratio too high?
Omkar Pharmachem's current PEG Ratio is 0.02. The Business Services industry median PEG Ratio is 1.18. Omkar Pharmachem's value of 0.02 is 98.3% below this industry median. Based on the distribution chart, Omkar Pharmachem ranks #1 out of 440 companies in the Business Services industry, which is in the top quartile — a strong position relative to peers. Overall, Omkar Pharmachem has a GF Score™ of 52/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Omkar Pharmachem's PEG Ratio compare to CTAS and CPRT?
According to the Business Services industry distribution chart, Omkar Pharmachem ranks #1 out of 440 companies for PEG Ratio. This places Omkar Pharmachem in the top 0% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.18. Omkar Pharmachem's value of 0.02 is 98.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Business Services company?
The median PEG Ratio among Business Services companies is 1.18, based on 440 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Omkar Pharmachem's current PEG Ratio of 0.02 is 98.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Omkar Pharmachem and its competitors. For the Business Services industry, the median PEG Ratio is 1.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omkar Pharmachem's current PEG Ratio is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omkar Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Omkar Pharmachem (BOM:532167) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹23.90, compared to a current price of ₹16.30 — trading 31.8% below its estimated fair value. The current PEG Ratio is 0.02 and 98.3% below the Business Services industry median of 1.18. Omkar Pharmachem's overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Omkar Pharmachem (BOM:532167), the current PEG Ratio is 0.02 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omkar Pharmachem (BOM:532167) Overvalued in 2026?
Based on GuruFocus' analysis, Omkar Pharmachem stock appears to be undervalued.
The current stock price of ₹16.30 is trading 31.8% below its estimated GF Value™ of ₹23.90.
GuruFocus considers Omkar Pharmachem to be Significantly Undervalued.
Key valuation signals for BOM:532167:
PEG Ratio: 0.02
GF Value™: ₹23.90 vs. price of ₹16.30 (31.8% below fair value)
Industry Position: 98.3% below the Business Services median (#1 of 440)
No single metric tells the full story. See the BOM:532167 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532167 has been successfully added to your 
